• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

健康筛查人群中血浆寡聚化淀粉样蛋白-β与脑白质病变的相关性。

Association of Plasma Oligomerized Amyloid-β and Cerebral White Matter Lesions in a Health Screening Population.

机构信息

Department of Neurology, Seoul National University Hospital, Seoul, South Korea.

Department of Neurology, College of Medicine, Seoul National University, Seoul, South Korea.

出版信息

J Alzheimers Dis. 2022;85(4):1835-1844. doi: 10.3233/JAD-215399.

DOI:10.3233/JAD-215399
PMID:34974433
Abstract

BACKGROUND

Cerebral white matter lesions (WML) are related to a higher risk of vascular and Alzheimer's dementia. Moreover, oligomerized amyloid-β (OAβ) can be measured from blood for dementia screening.

OBJECTIVE

We aimed to investigate the relationship of plasma OAβ levels with clinical and radiological variables in a health screening population.

METHODS

WML, other volumetric parameters of magnetic resonance images, cognitive assessment, and plasma OAβ level were evaluated.

RESULTS

Ninety-two participants were analyzed. The majority of participants' clinical dementia rating was 0 or 0.5 (96.7%). White matter hyperintensities (WMH) increased with age, but OAβ levels did not (r2 = 0.19, p < 0.001, r2 = 0.03, p = 0.10, respectively). No volumetric data, including cortical thickness/hippocampal volume, showed any significant correlation with OAβ. Log-WMH volume was positively correlated with OAβ (r = 0.24, p = 0.02), and this association was significant in the periventricular area. White matter signal abnormalities from 3D-T1 images were also correlated with the OAβ in the periventricular area (p = 0.039). Multivariate linear regression showed that log-WMH values were independently associated with OAβ (B = 0.879 (95% confidence interval 0.098 -1.660, p = 0.028)). Higher tertiles of WMH showed higher OAβ levels than lower tertiles showed (p = 0.044). Using a cutoff of 0.78 ng/mL, the high OAβ group had a larger WMH volume, especially in the periventricular area, than the low OAβ group (p = 0.036).

CONCLUSION

Both WML and plasma OAβ levels can be early markers for neurodegeneration in the healthcare population. The lesions, especially in the periventricular area, might be related to amyloid pathogenesis, which strengthens the importance of WML in the predementia stage.

摘要

背景

脑白质病变(WML)与血管性和阿尔茨海默病痴呆的风险增加有关。此外,可从血液中测量寡聚化的淀粉样β(OAβ),以用于痴呆筛查。

目的

我们旨在研究健康筛查人群中血浆 OAβ 水平与临床和影像学变量的关系。

方法

评估了 WML、磁共振图像的其他容积参数、认知评估和血浆 OAβ 水平。

结果

分析了 92 名参与者。大多数参与者的临床痴呆评定量表(CDR)为 0 或 0.5(96.7%)。脑白质高信号(WMH)随年龄增加而增加,但 OAβ 水平没有增加(r2=0.19,p<0.001,r2=0.03,p=0.10)。包括皮质厚度/海马体积在内的任何容积数据均与 OAβ 无显著相关性。WMH 体积的对数值与 OAβ 呈正相关(r=0.24,p=0.02),且这种相关性在脑室周围区域显著。3D-T1 图像的脑白质信号异常与脑室周围区域的 OAβ 也相关(p=0.039)。多元线性回归显示,WMH 值的对数值与 OAβ 独立相关(B=0.879(95%置信区间 0.098-1.660,p=0.028))。WMH 三分位较高者的 OAβ 水平高于三分位较低者(p=0.044)。使用 0.78ng/ml 的截断值,OAβ 水平较高组的 WMH 体积较大,尤其是在脑室周围区域,高于 OAβ 水平较低组(p=0.036)。

结论

WMH 和血浆 OAβ 水平均可作为医疗保健人群神经退行性变的早期标志物。病变,尤其是脑室周围区域的病变,可能与淀粉样蛋白发病机制有关,这增强了 WML 在痴呆前阶段的重要性。

相似文献

1
Association of Plasma Oligomerized Amyloid-β and Cerebral White Matter Lesions in a Health Screening Population.健康筛查人群中血浆寡聚化淀粉样蛋白-β与脑白质病变的相关性。
J Alzheimers Dis. 2022;85(4):1835-1844. doi: 10.3233/JAD-215399.
2
Can white matter hyperintensities based Fazekas visual assessment scales inform about Alzheimer's disease pathology in the population?基于 Fazekas 视觉评估量表的脑白质高信号能反映人群中的阿尔茨海默病病理吗?
Alzheimers Res Ther. 2024 Jul 10;16(1):157. doi: 10.1186/s13195-024-01525-5.
3
Plasma Oligomer β-Amyloid and White Matter Microstructural Integrity in Cognitively Normal Older Adults According to Cerebral Amyloid Deposition.根据脑淀粉样蛋白沉积情况,在认知正常的老年人群中,血浆寡聚β-淀粉样蛋白与脑白质微观结构完整性的关系。
J Prev Alzheimers Dis. 2023;10(4):837-846. doi: 10.14283/jpad.2023.87.
4
Reconsidering harbingers of dementia: progression of parietal lobe white matter hyperintensities predicts Alzheimer's disease incidence.重新审视痴呆症的先兆:顶叶白质高信号的进展可预测阿尔茨海默病的发病率。
Neurobiol Aging. 2015 Jan;36(1):27-32. doi: 10.1016/j.neurobiolaging.2014.07.019. Epub 2014 Jul 21.
5
Blood amyloid-β oligomerization associated with neurodegeneration of Alzheimer's disease.血液淀粉样-β寡聚体与阿尔茨海默病的神经退行性变有关。
Alzheimers Res Ther. 2019 May 10;11(1):40. doi: 10.1186/s13195-019-0499-7.
6
Association between increased levels of amyloid-β oligomers in plasma and episodic memory loss in Alzheimer's disease.血浆中淀粉样β寡聚体水平升高与阿尔茨海默病的情景记忆丧失有关。
Alzheimers Res Ther. 2019 Oct 25;11(1):89. doi: 10.1186/s13195-019-0535-7.
7
White matter hyperintensity topography in Alzheimer's disease and links to cognition.阿尔茨海默病患者脑白质高信号的分布特征及其与认知功能的相关性。
Alzheimers Dement. 2022 Mar;18(3):422-433. doi: 10.1002/alz.12410. Epub 2021 Jul 28.
8
Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions.脑淀粉样蛋白负担与特定后部白质区域的脑白质高信号位置有关。
Neurobiol Aging. 2019 Dec;84:225-234. doi: 10.1016/j.neurobiolaging.2019.08.001. Epub 2019 Aug 9.
9
Plasma soluble TREM2 is associated with white matter lesions independent of amyloid and tau.血浆可溶性 TREM2 与脑白质病变相关,与淀粉样蛋白和 tau 无关。
Brain. 2021 Dec 16;144(11):3371-3380. doi: 10.1093/brain/awab332.
10
White Matter Hyperintensities Potentiate Hippocampal Volume Reduction in Non-Demented Older Individuals with Abnormal Amyloid-β.白质高信号增强了淀粉样β蛋白异常的非痴呆老年人海马体积的减少。
J Alzheimers Dis. 2017;55(1):333-342. doi: 10.3233/JAD-160474.

引用本文的文献

1
Lateralizing Value of Artificial Intelligence-Based Segmentation Software in MRI-Negative Focal Epilepsy.基于人工智能的分割软件在MRI阴性局灶性癫痫中的定侧价值
J Epilepsy Res. 2024 Dec 10;14(2):59-65. doi: 10.14581/jer.24011. eCollection 2024 Dec.
2
White matter hyperintensities: a possible link between sarcopenia and cognitive impairment in patients with mild to moderate Alzheimer's disease.脑白质高信号:轻度至中度阿尔茨海默病患者肌肉减少症与认知障碍之间的可能联系。
Eur Geriatr Med. 2023 Oct;14(5):1037-1047. doi: 10.1007/s41999-023-00818-6. Epub 2023 Jun 18.